Primary coronary angioplasty for acute myocardial infarction with contraindication to thrombolysis. 1993

D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
Service de Cardiologie, Hôpital Bichat, Paris, France.

Patients with acute myocardial infarction (AMI) and contraindication to thrombolysis have a high mortality and morbidity with conventional medical treatment. Among 226 consecutive patients hospitalized within 6 hours of the onset of Q-wave AMI, 45 (20%) had contraindications to thrombolysis. All were treated by emergent primary angioplasty. Mean age of the 45 patients was 60 +/- 11 years and 8 (18%) were > or = 70 years old; 17 (38%) had multivessel disease and 5 (11%) presented with cardiogenic shock. Successful angioplasty was achieved in 42 of the 45 patients (93%) 52 +/- 27 minutes after admission and 238 +/- 100 minutes after the onset of pain. Overall in-hospital mortality was 9% (4 of 45). Neither major bleeding nor stroke occurred. There was 1 case of early symptomatic reocclusion, treated with emergent repeat angioplasty without reinfarction. Predischarge angiography in 33 patients showed only 1 silent reocclusion (3%). Ejection fraction at discharge was 46 +/- 13%. Repeat catheterization at 6 months in 19 patients showed 4 restenoses (21%) and 4 reocclusions (21%) of the infarct-related artery. There were 3 late deaths (2 noncardiac), which gave survival rates of 87 and 85% at 1 and 3 years, respectively, and event-free survival rates of 71 and 69% including in-hospital deaths. There were no cases of late reinfarction. Consequently, in this series, primary coronary angioplasty proved safe and highly effective in rapidly restoring sustained infarct-vessel patency during AMI, and led to a greater improvement in early and late outcomes than that reported in the literature for medically treated subjects in this high-risk subset for which thrombolytic therapy is contraindicated.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004630 Emergencies Situations or conditions requiring immediate intervention to avoid serious adverse results. Emergency
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006328 Cardiac Catheterization Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures. Catheterization, Cardiac,Catheterization, Heart,Heart Catheterization,Cardiac Catheterizations,Catheterizations, Cardiac,Catheterizations, Heart,Heart Catheterizations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075202 Contraindications A condition or factor associated with a recipient that makes the use of a drug, procedure, or physical agent improper or inadvisable. Contraindications may be absolute (life threatening) or relative (higher risk of complications in which benefits may outweigh risks). Contraindications, Physical Agent,Medical Contraindications,Agent Contraindication, Physical,Agent Contraindications, Physical,Contraindication,Contraindication, Medical,Contraindication, Physical Agent,Contraindications, Medical,Medical Contraindication,Physical Agent Contraindication,Physical Agent Contraindications

Related Publications

D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
April 2003, Lancet (London, England),
D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
April 2003, Lancet (London, England),
D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
April 2003, Lancet (London, England),
D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
January 1999, Cardiology in review,
D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
April 1997, The New England journal of medicine,
D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
April 1997, The New England journal of medicine,
D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
April 1997, The New England journal of medicine,
D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
March 2000, The New England journal of medicine,
D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
January 2003, Lancet (London, England),
D Himbert, and J M Juliard, and P G Steg, and G Badaoui, and S Baleynaud, and D Le Guludec, and M C Aumont, and R Gourgon
January 2003, Lancet (London, England),
Copied contents to your clipboard!